JHU (Baltimore)

The Clinical Research Site at Johns Hopkins, directed by Yukari Manabe, MD, occupies space on  the East Baltimore Medical Campus. The JHU CRS takes advantage of the many units available within Johns Hopkins Hospital, including Inpatient/Overnight Services for adult research participants, the Outpatient Research Unit, Inpatient/Outpatient Service for pediatric research participants, research nutrition services, and the Drug Development and Analysis Unit.

The HIV Care Program serves as the most important resource for patient referrals to ACTG clinical trials, and is also an important referral source for HPTN trials. The Service is directed by Dr. Manabe, and was founded in 1983. The principal components are summarized below:

Laboratory Facilities
All sample processing for virology assays for the CRS will be performed in the HIV Specialty Lab and includes a tissue culture room, specimen prep room, a PCR amplification room, a room for HIV antibody testing and a PCR detection room. The HIV/STD Research Laboratory is recognized internationally for expertise as a reference laboratory for all STDs, especially gonorrhea and chlamydia testing. Both the gonococcal and chlamydial sections of this laboratory are licensed by the State of Maryland and Clinical Laboratory Improvement Amendments (CLIA; ID # 21D0680509; State of Maryland laboratory permit #008 and 940247, respectively) for STD diagnostic evaluations, and are recognized as leading diagnostic labs in the United States.

Clinical Trials

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5308: A Prospective, Single-Arm, Open-Label Study to...

This study is being done with people who are infected with HIV, but do not show any signs of having HIV. They are also feeling...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More